| Authors: |
Gibbons JB; Program on Regulation, Therapeutics and Law, Division of Pharmacoepidemiology & Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Bandara S; Department of Health Policy & Management, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.; Department of Mental Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA., Cook BL; Department of Psychiatry, Cambridge Health Alliance, Harvard Medical School, Cambridge, Massachusetts, USA., Byrne L; Department of Health Policy & Management, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA., Sugarman OK; Department of Health Policy & Management, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA., Kerins L; Vital Strategies, New York, New York, USA., Pugh T; Vital Strategies, New York, New York, USA., Hulsey EG; Institute for Research, Education, and Training on Addictions, Pittsburgh, Pennsylvania, USA., Heller D; Vital Strategies, New York, New York, USA., Song M; Department of Health Services, Policy, and Practice, Brown University, Providence, Rhode Island, USA., Saloner B; Department of Health Services, Policy, and Practice, Brown University, Providence, Rhode Island, USA. |
